FlashDx Inc unveils next generation Sample-to-Answer Systems and expands test menu

Redwood city, California, Nov 13, 2023 – FlashDx Inc, a leader in near patient care affordable Molecular testing, is excited to announce the launch of its newest instrument lines, SPRT? 4T/8T/12T Sample-to-Answer Molecular Test Systems at MEDICA 2023 (Düsseldorf, Germany). These state-of-the-art instruments bring new levels of flexibility and access, featuring expandable multi-slot capabilities that allow healthcare providers to run up to 12 tests simultaneously in random access. Furthermore, FlashDx is widening its syndromic tests for Respiratory, Sexually Transmitted Infections and GBS to meet the growing demands.

“Our proprietary semi-Solid Phase Real Time PCR (SPRT?) technology is key to our competitive advantage. It enables qPCR accuracy for cartridge-based high multiplex syndromic tests.” explains Dr. Min Yue, CEO and co-founder of FlashDx Inc. The SPRT? technology ensures that healthcare providers can obtain laboratory standard data for molecular testing of up to 50 targets right where patient care is delivered. With just one minute of hands-on time and zero additional steps for sample preparation, the SPRT? 4T/8T/12T systems continue FlashDx's legacy of offering simplified workflows alongside accurate and affordable diagnostic solutions.

The company is also expanding its test cartridge menu to better address the needs of customers. Its existing portfolio of human In-Vitro Diagnostic (IVD) tests of comprehensive Respiratory panels (10-pathogen RP 1.1, 8 pathogen RP1.0, 4-plex panel) and GBS tests, will now be augmented with the SPRT? Sexually Transmitted Infections (STI) RUO Panel. This new panel can detect six (6) sexually transmitted pathogens in a single sample-to-answer cartridge and is currently available for research use only. An STI IVD panel cartridge is expected in 2024. Future releases of molecular and genetic panels will further diversify the company's diagnostic capabilities.

“The launch of these new products marks another significant step for FlashDx in redefining the way healthcare providers approach diagnostics.” announced Dr. Licen Lisa Xu, Chief Commercial Officer. ”With our innovative SPRT? 4T/8T/12T systems and expanded test offerings, we're delivering unparalleled quality and convenience; we're also open for development and OEM partners to join us in expanding the boundaries of what's possible in affordable healthcare.”

About FlashDx, Inc.

Founded by seasoned industry experts, FlashDx’s mission is to provide affordable, plug&play Molecular testing solutions that can be widely applied in hospitals, clinics and physician’s offices. The company received certification to ISO 9001:2015 and ISO 13485:2016 standards and has facilities in the United States and China, including R&D laboratories, GMP manufacturing plant, and Class 100K and 10K cleanrooms for cartridge manufacturing.

For media inquiries, partnerships, or more information about FlashDx, please reach out to:

Phone: +1 650 260 3737

Email: [email protected]